icon-    folder.gif   Conference Reports for NATAP  
 
  21st Conference on Retroviruses and
Opportunistic Infections
Boston, MA March 3 - 6, 2014
Back grey_arrow_rt.gif
 
 
 
All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection
 
 
  Reported by Jules Levin
Conference on Retroviruses and Opportunistic Infections
Boston, MA, March 3-6, 2014
 
Everson GT,1 Thuluvath PJ,2 Lawitz E,3 Hassanein T,4 Rodriguez-Torres M,5 Hawkins T,6 Rustgi V,7 Hinestrosa F,8 Levin JM,9 Sims KD10
 
1University of Colorado Denver, Aurora, CO; 2Mercy Medical Center and University of Maryland School of Medicine, Baltimore, MD; 3The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 4Southern California Liver Centers, Coronado, CA; 5Fundacion de Investigacion, San Juan, Puerto Rico; 6Southwest CARE Center, Santa Fe, NM; 7Metropolitan Research, Arlington, VA; 8Orlando Immunology Center, Orlando, FL; 9Dean Foundation for Health, Research and Education, Inc, Madison, WI; 10Bristol-Myers Squibb, Hopewell, NJ
 

HCV1.gif

1 UNITY 1:
http://www.clinicaltrials.gov/ct2/show/NCT01979939?term=daclatasvir+and+asunaprevir&rank=17
 
UNITY 2:
http://www.clinicaltrials.gov/ct2/show/NCT01973049?term=daclatasvir+and+asunaprevir&rank=10
 
CROI webcast:
http://www.croiwebcasts.org/console/player/22172?mediaType=slideVideo&
 

HCV2.gif

HCV3.gif

HCV4.gif

HCV5.gif

HCV6.gif

HCV7.gif

HCV8.gif

HCV9.gif

HCV10.gif